REDUCED INSULIN NEED IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)WITH IRON DEFICIENCY ANEMIA THREATED WITH SUCROSOMIAL IRON VS INTRAVENOUS SODIUM FERRIGLUCONATE. MULTICENTRIC PROSPECTIVE STUDY.
(Abstract release date: 05/19/16)
EHA Library. GIORDANO G. 06/09/16; 135034; PB2134
Dr. GIULIO GIORDANO
Contributions
Contributions
Abstract
Abstract: PB2134
Type: Publication Only
Background
About one out of four diabetic patient shows iron deficiency anemia. I.v. sodium ferrigluconate is frequently used as iron deficiency anemia therapy. The sucrosomial iron is a new compound used in the therapy, made of sucrose ester containing liposomal iron. Sodium ferrigluconate increases the amount of free radicals. The increase of free radicals increases inflammation. Inflammation reduces insulin sensitivity in diabetic patients.
Aims
To assess whether the use of sucrosomial iron involves less use of insulin in patients with T2DM with iron deficiency anemia
Methods
This study is a multicentric randomized study. We considered 40 T2DM patients with iron deficiency anemia, with TIBC saturation <10% and hemoglobin <10 g/dl, without documented infections, tumors or autoimmune diseases. All patients received diabetic diet. They received lispro insulin TID + glargine insulin once daily.In group A 20 patients, M: F = 12/8, median age 75 years (R65-82), median blood glucose 230 mg/dl (R170-350), median CRP at onset 10 mm/Ih (R2-22), were treated with sodium ferrigluconate 62.5 mg in 250 cc NS ic iv in 4 hours / day for 12 days. In group A, 10 patients had anemia by gastrointestinal hemorrhage, 5 by atrophic gastritis, 5 by insufficient intake.In group B, 20 patients, M: F = 11/9, median age 78 years (R67-83), median blood glucose 220 mg / dl (R180-380), median CRP at onset 12 mm/Ih (R2-20), were treated with sucrosomial iron 1CP 30 mg orally x 2 / day for 30 days. In group B, 12 patients had anemia by gastrointestinal hemorrhage, 4 by atrophic gastritis, 4 by insufficient intake.Differences between the two groups were not statistically significant.Statistical analysis was done with Fisher exact test and with Chi Square test.
Results
In group A at day 6 of iron support the median values of CRP were 38 mm/Ih (R4-127), with 5-documented infections (urinary 3, lung 1, skin 1); only 8 patients achieved blood glucose values
Conclusion
In diabetic patients with iron deficiency anemia supported with sucrosomial iron the median lispro insulin need appears to be lower than that of the patients supported with i.v. sodium ferrigluconate. This study needs confirmation on a larger cohort of patients.
Session topic: E-poster
Keyword(s): Anemia, Iron deficiency
Type: Publication Only
Background
About one out of four diabetic patient shows iron deficiency anemia. I.v. sodium ferrigluconate is frequently used as iron deficiency anemia therapy. The sucrosomial iron is a new compound used in the therapy, made of sucrose ester containing liposomal iron. Sodium ferrigluconate increases the amount of free radicals. The increase of free radicals increases inflammation. Inflammation reduces insulin sensitivity in diabetic patients.
Aims
To assess whether the use of sucrosomial iron involves less use of insulin in patients with T2DM with iron deficiency anemia
Methods
This study is a multicentric randomized study. We considered 40 T2DM patients with iron deficiency anemia, with TIBC saturation <10% and hemoglobin <10 g/dl, without documented infections, tumors or autoimmune diseases. All patients received diabetic diet. They received lispro insulin TID + glargine insulin once daily.In group A 20 patients, M: F = 12/8, median age 75 years (R65-82), median blood glucose 230 mg/dl (R170-350), median CRP at onset 10 mm/Ih (R2-22), were treated with sodium ferrigluconate 62.5 mg in 250 cc NS ic iv in 4 hours / day for 12 days. In group A, 10 patients had anemia by gastrointestinal hemorrhage, 5 by atrophic gastritis, 5 by insufficient intake.In group B, 20 patients, M: F = 11/9, median age 78 years (R67-83), median blood glucose 220 mg / dl (R180-380), median CRP at onset 12 mm/Ih (R2-20), were treated with sucrosomial iron 1CP 30 mg orally x 2 / day for 30 days. In group B, 12 patients had anemia by gastrointestinal hemorrhage, 4 by atrophic gastritis, 4 by insufficient intake.Differences between the two groups were not statistically significant.Statistical analysis was done with Fisher exact test and with Chi Square test.
Results
In group A at day 6 of iron support the median values of CRP were 38 mm/Ih (R4-127), with 5-documented infections (urinary 3, lung 1, skin 1); only 8 patients achieved blood glucose values
Conclusion
In diabetic patients with iron deficiency anemia supported with sucrosomial iron the median lispro insulin need appears to be lower than that of the patients supported with i.v. sodium ferrigluconate. This study needs confirmation on a larger cohort of patients.
Session topic: E-poster
Keyword(s): Anemia, Iron deficiency
Abstract: PB2134
Type: Publication Only
Background
About one out of four diabetic patient shows iron deficiency anemia. I.v. sodium ferrigluconate is frequently used as iron deficiency anemia therapy. The sucrosomial iron is a new compound used in the therapy, made of sucrose ester containing liposomal iron. Sodium ferrigluconate increases the amount of free radicals. The increase of free radicals increases inflammation. Inflammation reduces insulin sensitivity in diabetic patients.
Aims
To assess whether the use of sucrosomial iron involves less use of insulin in patients with T2DM with iron deficiency anemia
Methods
This study is a multicentric randomized study. We considered 40 T2DM patients with iron deficiency anemia, with TIBC saturation <10% and hemoglobin <10 g/dl, without documented infections, tumors or autoimmune diseases. All patients received diabetic diet. They received lispro insulin TID + glargine insulin once daily.In group A 20 patients, M: F = 12/8, median age 75 years (R65-82), median blood glucose 230 mg/dl (R170-350), median CRP at onset 10 mm/Ih (R2-22), were treated with sodium ferrigluconate 62.5 mg in 250 cc NS ic iv in 4 hours / day for 12 days. In group A, 10 patients had anemia by gastrointestinal hemorrhage, 5 by atrophic gastritis, 5 by insufficient intake.In group B, 20 patients, M: F = 11/9, median age 78 years (R67-83), median blood glucose 220 mg / dl (R180-380), median CRP at onset 12 mm/Ih (R2-20), were treated with sucrosomial iron 1CP 30 mg orally x 2 / day for 30 days. In group B, 12 patients had anemia by gastrointestinal hemorrhage, 4 by atrophic gastritis, 4 by insufficient intake.Differences between the two groups were not statistically significant.Statistical analysis was done with Fisher exact test and with Chi Square test.
Results
In group A at day 6 of iron support the median values of CRP were 38 mm/Ih (R4-127), with 5-documented infections (urinary 3, lung 1, skin 1); only 8 patients achieved blood glucose values
Conclusion
In diabetic patients with iron deficiency anemia supported with sucrosomial iron the median lispro insulin need appears to be lower than that of the patients supported with i.v. sodium ferrigluconate. This study needs confirmation on a larger cohort of patients.
Session topic: E-poster
Keyword(s): Anemia, Iron deficiency
Type: Publication Only
Background
About one out of four diabetic patient shows iron deficiency anemia. I.v. sodium ferrigluconate is frequently used as iron deficiency anemia therapy. The sucrosomial iron is a new compound used in the therapy, made of sucrose ester containing liposomal iron. Sodium ferrigluconate increases the amount of free radicals. The increase of free radicals increases inflammation. Inflammation reduces insulin sensitivity in diabetic patients.
Aims
To assess whether the use of sucrosomial iron involves less use of insulin in patients with T2DM with iron deficiency anemia
Methods
This study is a multicentric randomized study. We considered 40 T2DM patients with iron deficiency anemia, with TIBC saturation <10% and hemoglobin <10 g/dl, without documented infections, tumors or autoimmune diseases. All patients received diabetic diet. They received lispro insulin TID + glargine insulin once daily.In group A 20 patients, M: F = 12/8, median age 75 years (R65-82), median blood glucose 230 mg/dl (R170-350), median CRP at onset 10 mm/Ih (R2-22), were treated with sodium ferrigluconate 62.5 mg in 250 cc NS ic iv in 4 hours / day for 12 days. In group A, 10 patients had anemia by gastrointestinal hemorrhage, 5 by atrophic gastritis, 5 by insufficient intake.In group B, 20 patients, M: F = 11/9, median age 78 years (R67-83), median blood glucose 220 mg / dl (R180-380), median CRP at onset 12 mm/Ih (R2-20), were treated with sucrosomial iron 1CP 30 mg orally x 2 / day for 30 days. In group B, 12 patients had anemia by gastrointestinal hemorrhage, 4 by atrophic gastritis, 4 by insufficient intake.Differences between the two groups were not statistically significant.Statistical analysis was done with Fisher exact test and with Chi Square test.
Results
In group A at day 6 of iron support the median values of CRP were 38 mm/Ih (R4-127), with 5-documented infections (urinary 3, lung 1, skin 1); only 8 patients achieved blood glucose values
Conclusion
In diabetic patients with iron deficiency anemia supported with sucrosomial iron the median lispro insulin need appears to be lower than that of the patients supported with i.v. sodium ferrigluconate. This study needs confirmation on a larger cohort of patients.
Session topic: E-poster
Keyword(s): Anemia, Iron deficiency
{{ help_message }}
{{filter}}